Philippot, Quentin
Bastard, Paul
Puel, Anne
Casanova, Jean-Laurent
Cobat, Aurélie
Laouénan, Cédric
Tardivon, Coralie
Crestani, Bruno
Borie, Raphael
Funding for this research was provided by:
Assistance Publique-Hôpitaux de Paris
MD-PhD program of INSERM
Article History
Received: 30 November 2022
Accepted: 13 March 2023
First Online: 20 March 2023
Declarations
:
: This study was approved by the “Comité de Protection des Personnes Ile de France 1” (n° 0911932) and was conducted in accordance with the Helsinki Declaration. Written informed consent was obtained for all the participants.
: Not applicable.
: Q.P. received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Gilead. J.-L.C. is an inventor on patent application PCT/US2021/042741, filed July 22, 2021, submitted by The Rockefeller University that covers diagnosis of susceptibility to, and treatment of, viral disease and viral vaccines, including Covid-19 and vaccine-associated diseases. B.C. received grants from BMS, Boehringer Ingelheim and Roche, consulting fees from apellis, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim, BMS, Roche, Sanofi, Novartis, Astra Zeneca and Chiesi, and receipt of equipment, materials, drugs, medical writing, gifts or other services from Translate Bio. R.B. received grants from Roche, Boehringer Ingelheim and Sanofi, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Roche, Boehringer Ingelheim and Sanofi, and participated on a Data Safety Monitoring Board or Advisory Board for SAvara.